Published date: Sep 20 2015

Journal Title: KnE Life Sciences

Issue title: International Conference on Biological Sciences (ICBS-2013)

Pages: 481-483

DOI: 10.18502/kls.v2i1.196

Yulia SariDepartment of Parasitology Faculty of Medicine, Sebelas Maret University Biomedical Laboratory Faculty of Medicine, Sebelas Maret University Center of Biotechnology and Biodiversity Research and Development, Sebelas Maret University

Sri HaryatiDepartment of Parasitology Faculty of Medicine, Sebelas Maret University Center of Biotechnology and Biodiversity Research and Development, Sebelas Maret University

Dhani RedhonoDepartment of Internal Medicine, Faculty of Medicine, Sebelas Maret University

Afiono Agung Prasetyoafie.agp.la@gmail.comCenter of Biotechnology and Biodiversity Research and Development, Sebelas Maret University Department of Internal Medicine, Faculty of Medicine, Sebelas Maret University Department of Microbiology Faculty of Medicine, Sebelas Maret University

Background: The CCR5.32 polymorphism (a naturally occurring 32-bp deletion in CCR5) influences the ability of HIV-1 to infect the target cells. Homozygosity for CCR5.32 prevents infection of HIV-1 R5 strain, while the heterozygous is associated with lower plasma viral load and delayed progression to acquired immune deficiency syndrome (AIDS). However, there is no report about the presentation of CCR5.32 polymorphisms in Indonesian HIV patients. The aim of this study is to detect CCR5.32 polymorphisms in Indonesian HIV patients, especially in Voluntary Counseling and Testing Moewardi General Hospital Surakarta, Indonesia. In an ongoing molecular epidemiology study of blood borne virus, 154 HIV patients in Moewardi General Hospital Surakarta were used for the study. The blood samples were collected during November – December 2011. The blood samples were aliquoted and fractionated. The DNA was extracted from all blood samples, and subjected for the PCR assay to detect the presentation of CCR5.32 polymorphisms. Internal amplification control was included in all assays. PCR products were analyzed in 3% agarose. The results showed that CCR5.32 polymorphism was not detected in all blood samples. So it can be concluded that all patients in this study had the CCR5 wild type.

Keywords: CCR5.32, HIV, Indonesia.

Didigu, C.A., and R.W. Doms. 2012. Novel approaches to inhibit HIV entry. Viruses, vol. 4:309-324.
Grivel, J.C., R.J. Shattock, and L.B. Margolis. 2011. Selective transmission of R5 HIV-1 variants: Where is the gatekeeper? J Transl Med, vol. 9 Suppl 1:S6.
Gupta, A., and H. Padh. 2012. The global distribution of CCR5 delta 32 polymorphism: role in HIV-1 protection. BMC Infect Dis, vol. 12 (Suppl 1):O16.
Huang, Y., W.A. Paxton, S.M. Wolinsky, A.U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, K. Kunstman, D. Erickson, E. Dragon, N.R. Landau, J. Phair, D.D. Ho, and R.A. Koup. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med, vol. 2:1240-1243.
Hyde, C.L., A. Macinnes, F.A. Sanders, J.F. Thompson, R.A. Mazzarella, O. Faergeman, D.F. van Wijk, L. Wood, M. Lira, and S.A. Paciga. 2010. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet, vol. 3:162-168.
Liu, S., C. Kong, J. Wu, H. Ying, and H. Zhu. 2012. Effect of CCR5-D32 heterozygosity on HIV-1 susceptibility: A meta-analysis. PLoS ONE, vol. 7: e35020.